Shares of Cortexyme, Inc. (NASDAQ:CRTX) have been assigned an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.

Brokerages have set a 12-month consensus price target of $41.67 for the company and are expecting that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cortexyme an industry rank of 79 out of 256 based on the ratings given to its competitors.

A number of analysts have recently commented on the company. Zacks Investment Research raised Cortexyme from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Wednesday, August 14th. JMP Securities assumed coverage on Cortexyme in a report on Monday, June 3rd. They issued a “mkt outperform” rating and a $53.00 target price on the stock. Canaccord Genuity assumed coverage on Cortexyme in a report on Monday, June 3rd. They issued a “buy” rating and a $42.00 target price on the stock. Bank of America assumed coverage on Cortexyme in a report on Monday, June 3rd. They issued a “neutral” rating and a $28.00 target price on the stock. Finally, Credit Suisse Group assumed coverage on Cortexyme in a report on Monday, June 3rd. They issued an “underperform” rating and a $14.00 target price on the stock.

In related news, insider Epiq Capital Group, Llc bought 4,965 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were acquired at an average cost of $25.35 per share, for a total transaction of $125,862.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in shares of Cortexyme during the second quarter valued at $78,000. Wells Fargo & Company MN purchased a new position in shares of Cortexyme during the second quarter valued at $191,000. Bank of New York Mellon Corp purchased a new position in shares of Cortexyme during the second quarter valued at $349,000. Landscape Capital Management L.L.C. purchased a new position in shares of Cortexyme during the second quarter valued at $535,000. Finally, Northern Trust Corp purchased a new position in shares of Cortexyme during the second quarter valued at $991,000. Institutional investors and hedge funds own 7.48% of the company’s stock.

Shares of CRTX traded down $2.78 during midday trading on Monday, reaching $25.62. The stock had a trading volume of 35,032 shares, compared to its average volume of 86,587. Cortexyme has a 52 week low of $19.35 and a 52 week high of $47.50. The firm has a 50 day moving average of $26.75.

Cortexyme Company Profile

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

Featured Story: Why do commodities matter?

Get a free copy of the Zacks research report on Cortexyme (CRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.